IgG glycome in colorectal cancer

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 3078-3086

  Vučković, Frano ^a   Theodoratou, Evropi ^b,c   Thaçi, Kujtim ^a   Timofeeva, Maria ^c   Vojta, Aleksandar ^d   Štambuk, Jerko ^a   Pučić Baković, Maja ^a   Rudd, Pauline M ^e   Derek, Lovorka ^f   Servis, Dražen ^g   Wennerström, Annika ^h   Farrington, Susan M ^c   Perola, Markus ^h   Aulchenko, Yurii ⁱ   Dunlop, Malcolm G ^c   Campbell, Harry ^b,c   Lauc, Gordan ^a,j  

^a GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING   (Ireland)

^f University of Zagreb   (Croatia)

^g Chirurgische Klinik   (Germany)

^h NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

ⁱ PolyOmica   (Netherlands)

^j UNIVERSITY OF ZAGREB   (Croatia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; IMMUNOGLOBULIN G; GLYCOSYLATED IGG; TUMOR MARKER;

ADULT; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; ENVIRONMENTAL FACTOR; FEMALE; FUCOSYLATION; GLYCOBIOLOGY; GLYCOSYLATION; HEREDITY; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIALYLATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CASE CONTROL STUDY; COLORECTAL TUMOR; FEEDING BEHAVIOR; IMMUNOLOGY; MIDDLE AGED; PROTEIN PROCESSING; QUESTIONNAIRE;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEEDING BEHAVIOR; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROTEIN PROCESSING, POST-TRANSLATIONAL; SURVEYS AND QUESTIONNAIRES;

EID: 84975045730     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1867     Document Type: Article

References (47)

1. Hudak JE, Bertozzi CR. Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem Biol 2014;21:16-37.
2. Walt D, Aoki-Kinoshita KF, Bendiak B, Bertozzi CR, Boons GJ, Darvill A, et al. Transforming glycoscience: a roadmap for the future. Washington: Nacional Academies Press; 2012.
3. Wolfert MA, Boons GJ. Adaptive immune activation: glycosylation does matter. Nat Chem Biol 2013;9:776-84.
4. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
5. Burnet M. Cancer; a biological approach. I. The processes of control. Br. Med J 1957;1:779-86.
6. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
7. Kapur R, Einarsdottir HK, Vidarsson G. IgG-effector functions: "the good, the bad and the ugly". Immunol Lett 2014;160:139-44.
8. Quast I, Lunemann JD. Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol 2014;34:S51-5.
9. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 2012;12:13.
10. Gornik O, Pavic T, Lauc G. Alternative glycosylation modulates function of IgG and other proteins - Implications on evolution and disease. Biochim Biophys Acta 2012;1820:1318-26.
11. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 2011;10:M111010090.
12. Kris?tić J, Zoldos? V, Lauc G. Complex genetics of protein N-glycosylation. In: Endo T, Seeberger PH, Hart GW, Wong C-H, Taniguchi N, editors. Glycoscience: biology and medicine : Japan; 2014. p. 1-7.
13. Lauc G, Huffman JE, Pucic M, Zgaga L, Adamczyk B, Muzinic A, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet 2013;9:e1003225.
14. Trbojević Akmačić I, Ventham NT, Theodoratou E, Vučković F, Kennedy NA, Kris?tić J, et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin g glycome. Inflamm Bowel Dis 2015;21:1237-47.
15. Vučković F, Kris?tić J, Gudelj I, Artacho MT, Keser T, Pezer M, et al. Systemic lupus erythematosus associates with the decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol 2015; 67:2978-89.
16. Theodoratou E, Kyle J, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R, et al. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2007;16:684-93.
17. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Mannisto S, Sundvall J, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;39:504-18.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995: 289-300.
19. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10.
20. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007;5:1263-75.
21. Tsukamoto S, Ishikawa T, Iida S, Ishiguro M, Mogushi K, Mizushima H, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res 2011;17:2444-50.
22. Alhopuro P, Sammalkorpi H, Niittymaki I, Bistrom M, Raitila A, Saharinen J, et al. Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer 2012;130:1558-66.
23. R-Core-Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
24. Novokmet M, Lukic E, Vuckovic F, Duric Z, Keser T, Rajsl K, et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep 2014;4:4347.
25. Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, Yu CJ, et al. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci USA 2013;110:630-5.
26. Wang X, Chen J, Li QK, Peskoe SB, Zhang B, Choi C, et al. Overexpression of alpha (1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology 2014;24:935-44.
27. Zhao YP, Xu XY, Fang M, Wang H, You Q, Yi CH, et al. Decreased corefucosylation contributes to malignancy in gastric cancer. PLoS One 2014;9: e94536.
28. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13: 176-89.
29. Kristic J, Vuckovic F, Menni C, Klaric L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol 2014; 69:779-89.
30. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316:452-7.
31. Dube R, Rook GA, Steele J, Brealey R, Dwek R, Rademacher T, et al. Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. Gut 1990;31:431-4.
32. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers 2008;25:267-78.
33. Menni C, Keser T, Mangino M, Bell JT, Erte I, Akmacic I, et al. Glycosylation of Immunoglobulin G: Role of genetic and epigenetic influences. PLoS One 2013;8:e82558.
34. Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 2013;74:234-41.
35. Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 2010;62:2239-48.
36. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8.
37. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
38. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
39. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032-6.
40. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
41. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 2006;12:2879-87.
42. Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006;43: 1183-93.
43. Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 2013;19:1126-38.
44. Oppenheim DE, Spreafico R, Etuk A, Malone D, Amofah E, Pena-Murillo C, et al. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer 2014;110:1221-7.
45. Kapur R, Kustiawan I, Vestrheim A, Koeleman CA, Visser R, Einarsdottir HK, et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 2014;123:471-80.
46. Biburger M, Lux A, Nimmerjahn F. How immunoglobulin G antibodies kill target cells: revisiting an old paradigm. Adv Immunol 2014;124:67-94.
47. Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep 2014;4:6145.